Comparison of Visual Acuity Outcomes of Enhanced Monofocal Versus Standard Monofocal Intraocular Lenses from a Randomized, Multicenter, Active-Controlled Trial.

IF 2.9 3区 医学 Q1 OPHTHALMOLOGY
Robert Edward T Ang, Ramin Khoramnia, Harvey S Uy, Peter Hoffmann, Robert D Anello, Dominik Zalewski, Kai Januschowski, Pablo de Arriba Palomero, Daniel Böhringer, Marta Ibarz Barberá, Eckart Bertelmann, Slawomir Cisiecki, H Burkhard Dick, Katrin Lorenz, Gerd U Auffarth, Ramón Ruiz-Mesa, Alvin S Relucio
{"title":"Comparison of Visual Acuity Outcomes of Enhanced Monofocal Versus Standard Monofocal Intraocular Lenses from a Randomized, Multicenter, Active-Controlled Trial.","authors":"Robert Edward T Ang, Ramin Khoramnia, Harvey S Uy, Peter Hoffmann, Robert D Anello, Dominik Zalewski, Kai Januschowski, Pablo de Arriba Palomero, Daniel Böhringer, Marta Ibarz Barberá, Eckart Bertelmann, Slawomir Cisiecki, H Burkhard Dick, Katrin Lorenz, Gerd U Auffarth, Ramón Ruiz-Mesa, Alvin S Relucio","doi":"10.3928/1081597X-20250218-01","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To compare visual performance of the Vivinex Impress enhanced monofocal intraocular lens (IOL) (HOYA Surgical Optics) with the Acrysof IQ monofocal IOL (Alcon Laboratories, Inc).</p><p><strong>Methods: </strong>In this multicenter, active-controlled trial, participants were randomized 2:1 to bilateral implantation with the enhanced monofocal (test) or standard monofocal (control) IOL and examined through 12 months postoperatively for visual acuities, refractive outcomes, defocus curves, and pupil diameters.</p><p><strong>Results: </strong>Ninety-eight test and 46 control participants completed testing for the first implanted eye. The test arm demonstrated a statistically significant benefit in monocular distance-corrected intermediate visual acuity (DCIVA) (photopic: 1.2 lines, <i>P</i> < .001; mesopic: 0.7 lines, <i>P</i> = .01) and uncorrected intermediate visual acuity (0.8 lines; <i>P</i> < .001) but no significant difference in monocular corrected distance visual acuity (<i>P</i> = .07). Using a stepwise regression analysis for DCIVA, the final model (adjusted R-square, 0.31) identified three significant predictor variables (age, pupil diameter, and treatment arm). Photopic defocus curves showed the test arm produced better monocular visual acuity from -1.00 through -2.50 D than the control arm. The intermediate vision benefit of the test IOL is independent of pupil size and axial length. Cumulative and persistent adverse events for the test IOL did not exceed the Safety and Performance Endpoint rates per International Organization for Standardization 11979-7.</p><p><strong>Conclusions: </strong>Compared to a standard monofocal IOL, the Vivinex Impress enhanced monofocal IOL offers an extended range of vision, with significant improvements in intermediate vision and a DCIVA benefit unaffected by pupil size and axial length. This IOL is safe and effective for patients seeking improved intermediate vision following cataract surgery. <b>[<i>J Refract Surg</i>. 2025;41(4):e300-e309.]</b>.</p>","PeriodicalId":16951,"journal":{"name":"Journal of refractive surgery","volume":"41 4","pages":"e300-e309"},"PeriodicalIF":2.9000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of refractive surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3928/1081597X-20250218-01","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To compare visual performance of the Vivinex Impress enhanced monofocal intraocular lens (IOL) (HOYA Surgical Optics) with the Acrysof IQ monofocal IOL (Alcon Laboratories, Inc).

Methods: In this multicenter, active-controlled trial, participants were randomized 2:1 to bilateral implantation with the enhanced monofocal (test) or standard monofocal (control) IOL and examined through 12 months postoperatively for visual acuities, refractive outcomes, defocus curves, and pupil diameters.

Results: Ninety-eight test and 46 control participants completed testing for the first implanted eye. The test arm demonstrated a statistically significant benefit in monocular distance-corrected intermediate visual acuity (DCIVA) (photopic: 1.2 lines, P < .001; mesopic: 0.7 lines, P = .01) and uncorrected intermediate visual acuity (0.8 lines; P < .001) but no significant difference in monocular corrected distance visual acuity (P = .07). Using a stepwise regression analysis for DCIVA, the final model (adjusted R-square, 0.31) identified three significant predictor variables (age, pupil diameter, and treatment arm). Photopic defocus curves showed the test arm produced better monocular visual acuity from -1.00 through -2.50 D than the control arm. The intermediate vision benefit of the test IOL is independent of pupil size and axial length. Cumulative and persistent adverse events for the test IOL did not exceed the Safety and Performance Endpoint rates per International Organization for Standardization 11979-7.

Conclusions: Compared to a standard monofocal IOL, the Vivinex Impress enhanced monofocal IOL offers an extended range of vision, with significant improvements in intermediate vision and a DCIVA benefit unaffected by pupil size and axial length. This IOL is safe and effective for patients seeking improved intermediate vision following cataract surgery. [J Refract Surg. 2025;41(4):e300-e309.].

来自一项随机、多中心、主动对照试验的增强单焦点人工晶状体与标准单焦点人工晶状体的视力结果比较
目的:比较Vivinex Impress增强单焦点人工晶状体(HOYA Surgical Optics)和Acrysof IQ单焦点人工晶状体(Alcon Laboratories, Inc)的视觉性能。方法:在这项多中心主动对照试验中,参与者按2:1随机分为双侧植入增强单焦点(试验)或标准单焦点(对照)IOL,并在术后12个月内检查视力、屈光结果、离焦曲线和瞳孔直径。结果:98名受试者和46名对照受试者完成了首次植入眼的测试。试验组在单眼距离矫正的中间视力(DCIVA)方面显示出统计学上显著的益处(光度:1.2线,P < 0.001;中观:0.7线,P = 0.01)和未矫正的中间视力(0.8线;P < 0.001),但单眼矫正距离视力差异无统计学意义(P = 0.07)。对DCIVA进行逐步回归分析,最终模型(调整r方,0.31)确定了三个显著的预测变量(年龄、瞳孔直径和治疗组)。光离焦曲线显示,在-1.00 ~ -2.50 D范围内,测试组的单眼视力优于对照组。测试人工晶体的中间视力效益与瞳孔大小和眼轴长度无关。试验人工晶状体的累积和持续不良事件没有超过国际标准化组织11979-7规定的安全性和性能终点率。结论:与标准单焦点IOL相比,Vivinex Impress增强单焦点IOL提供了更大的视力范围,显著改善了中间视力,DCIVA的益处不受瞳孔大小和眼轴长度的影响。这种人工晶状体对于白内障术后寻求改善中间视力的患者是安全有效的。[J].中华眼科杂志,2015;41(4):893 - 893。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.10
自引率
12.50%
发文量
160
审稿时长
4-8 weeks
期刊介绍: The Journal of Refractive Surgery, the official journal of the International Society of Refractive Surgery, a partner of the American Academy of Ophthalmology, has been a monthly peer-reviewed forum for original research, review, and evaluation of refractive and lens-based surgical procedures for more than 30 years. Practical, clinically valuable articles provide readers with the most up-to-date information regarding advances in the field of refractive surgery. Begin to explore the Journal and all of its great benefits such as: • Columns including “Translational Science,” “Surgical Techniques,” and “Biomechanics” • Supplemental videos and materials available for many articles • Access to current articles, as well as several years of archived content • Articles posted online just 2 months after acceptance.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信